Sovateltide

Summary

Sovateltide (Tycamzzi™) is a synthetic peptide that selectively activates endothelin‑B (ET_B) receptors. It is approved in India for the treatment of acute cerebral ischemic stroke when administered within 24 hours of symptom onset. The drug is given intravenously and is intended to improve neurological recovery after stroke.

Mechanism of Action

By binding to ET_B receptors on endothelial and neural cells, sovateltide triggers vasodilation and increases cerebral blood flow. ET_B activation also initiates anti‑apoptotic signaling, stimulates release of neurotrophic factors, and promotes proliferation and differentiation of neural progenitor cells, thereby supporting neuroprotection and tissue repair after ischemic injury.

What the Research Shows

A multicentre, randomised, double‑blind Phase III trial in India (158 patients) compared three intravenous doses of sovateltide (0.3 µg/kg) with placebo, both on standard of care. At 90 days, the odds of achieving a modified Rankin Scale of 0‑2 were 2.75‑fold higher (22.7% absolute increase) and the odds of an NIHSS ≤5 were 2.67‑fold higher (17.0% absolute increase). Intracranial haemorrhage rates were similar between groups. A systematic review of seven rat middle‑cerebral‑artery‑occlusion studies found no mortality in sovateltide‑treated animals versus higher mortality in controls, and reported reduced neurological deficits, smaller infarct volumes, and enhanced neurogenesis. Phase I data indicated good tolerability, and ongoing trials are exploring hypoxic‑ischemic encephalopathy, spinal‑cord injury and Alzheimer’s disease.

Reported Benefits

Clinical data show that sovateltide can increase the proportion of stroke patients attaining functional independence (mRS 0‑2) and lower neurological deficit scores (NIHSS ≤5) at 90 days. Animal studies corroborate neuroprotective effects, including reduced infarct size and improved motor performance. The drug was well tolerated in early‑phase studies, with adverse events not attributed to the peptide.

Limitations of the Evidence

Evidence for efficacy rests on a single Phase III trial conducted in India; broader multinational confirmation is pending (RESPECT‑ETB trial). Sample size is modest, and long‑term outcomes beyond three months are not reported. Data for other neurological conditions remain pre‑clinical or in early clinical phases, and head‑to‑head comparisons with existing stroke therapies are lacking.

Safety Considerations

The Phase III study reported similar rates of intracranial haemorrhage in sovateltide and placebo groups (≈9%). No adverse events were directly linked to the peptide, and Phase I trials described it as safe and tolerable at therapeutic doses. Nevertheless, clinicians should monitor for bleeding complications, especially in patients with high haemorrhagic risk, until larger safety datasets become available.

How It Is Administered

Sovateltide is administered intravenously at a dose of 0.3 µg per kilogram of body weight. The regimen consists of three infusions given at intervals of about three hours on each of Days 1, 3, and 6 after stroke onset. The drug is supplied as a sterile solution for IV infusion.

Routes of Administration

Goals & Uses

• Reduction of infarct volumeNeuroprotectionLow
• Neurological recovery after acute ischemic strokeNeuroprotection / NeurorestorationModerate
• Acute ischemic stroke treatmentNeurologyModerate
• Promotion of neurogenesisNeuroregenerationModerate
• Cerebral angiogenesisVascular RemodelingLow

Contraindications

• Known hypersensitivity to sovateltide or excipientsAllergy/ImmunologyHigh
• Severe hepatic impairmentOrganModerateLiver function concerns
• Known hypersensitivity to sovateltide or any excipientsAllergyModerate
• Hemorrhagic strokeNeurologicalHigh

Adverse Effects

• Injection site reactionsLocalUncommon
• HeadacheNeurologicCommonPain in the head or upper neck
• HypotensionCardiovascularUncommonLow blood pressure
• NauseaGastrointestinalCommonFeeling of sickness or urge to vomit
• Transient hypotensionCardiovascularUncommon

Drug Interactions

• Tissue plasminogen activator (tPA / alteplase)Low
• Concurrent vasodilatorsModerate
• Antihypertensive agentsModerate
• Endothelin receptor antagonists (e.g., bosentan, ambrisentan)High

Population Constraints

• Patients with active malignancyOncologyRelative
• Severe renal impairmentOrgan ImpairmentRelative
• Pediatric patientsAgeAbsolute
• Pregnant womenReproductiveRelative

Regulatory Status

• European UnionUnapprovedNo marketing authorization in the European Union.
• United StatesUnapprovedInvestigational; not approved by FDA.
• United KingdomUnapprovedNot licensed by MHRA.

Has received regulatory approval in India (CDSCO) for acute ischemic stroke as an adjunct to standard of care. Designated as an investigational new drug (IND) in the US context. Developed by Pharmazz Inc. Phase III trial results reported from India.

Evidence & Sources

• Efficacy and Safety of Sovateltide in Patients with Acute Cerebral Ischaemic Stroke: A Randomised, Double-Blind, Placebo-Controlled, Multicentre, Phase III Clinical Trial
  Journal ArticleModerateGulati A, et al.2024-01-01T00:00:00.000000Z
• Sovateltide: First Approval
  Journal ArticleModerateKeam SJ2023-01-01T00:00:00.000000Z
• The Effects of IRL-1620 in Post-ischemic Brain Injury: A Systematic Review and Meta-analysis of Experimental Studies
  Journal ArticleHighMoustakas D, et al.2024-01-01T00:00:00.000000Z
• Next-generation therapeutics and renaissance of legacy drugs targeting the endothelin system
  Journal ArticleModerateDavenport A, et al.2026-01-01T00:00:00.000000Z
• Sovateltide Mediated Endothelin B Receptors Agonism and Curbing Neurological Disorders
  Journal ArticleModerateRanjan AK, Gulati A2022-01-01T00:00:00.000000Z
• Advances in Therapies to Treat Neonatal Hypoxic-Ischemic Encephalopathy
  Journal ArticleModerateRanjan AK, Gulati A2023-01-01T00:00:00.000000Z

Frequently Asked Questions